SELLAS adds oncology experts to advisory board

NEW YORK - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a biopharmaceutical company engaged in developing cancer therapies, announced today the expansion of its Scientific Advisory Board (SAB) with the addition of two renowned oncology specialists, Philip C. Amrein, MD, and Alex Kentsis, MD, PhD. The appointments come as SELLAS prepares for significant upcoming milestones in its clinical programs. According to InvestingPro data, the company maintains a strong financial position with a current ratio of 4.64, indicating robust liquidity to fund its development programs.

Dr. Amrein, affiliated with Harvard Medical School and Massachusetts General Hospital, brings extensive experience in leukemia treatment and clinical trials. Dr. Kentsis, from Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, contributes a deep understanding of pediatric oncology and developmental therapeutics. The company’s stock has shown strong momentum, with a 45.45% price return over the past six months, reflecting growing investor confidence in its strategic direction.

Angelos Stergiou, MD, President and CEO of SELLAS, expressed confidence that the expertise of Drs. Amrein and Kentsis will be instrumental in advancing the company’s lead product candidates. These include GPS, a therapy targeting the WT1 protein found in various tumor types, and SLS009, a small molecule CDK9 inhibitor showing promise in acute myeloid leukemia (AML) patients with poor prognostic factors.

SELLAS anticipates reaching critical points in its clinical trials this year, including full topline Phase 2 data for SLS009 and the final analysis of the Phase 3 REGAL trial for GPS in AML. These developments could pave the way for potential regulatory filings and commercialization efforts.

The company’s lead candidates reflect its commitment to addressing a broad spectrum of hematologic malignancies and solid tumors. GPS is licensed from Memorial Sloan Kettering Cancer Center, and SLS009 has demonstrated encouraging response rates in AML patients.

While SELLAS’s press release statement contains forward-looking expectations for its clinical development programs, these are subject to the usual risks and uncertainties associated with oncology product development and regulatory approval processes. Analyst price targets range from $4 to $7.50, suggesting significant potential upside from current levels. InvestingPro subscribers can access additional insights, including 8 more key tips about SELLAS’s financial health and market position.

This news is based on a press release statement from SELLAS Life Sciences Group, Inc.

In other recent news, SELLAS Life Sciences Group, Inc. has shared promising results from its Phase 2 trial of SLS009, a drug under investigation for treating relapsed/refractory acute myeloid leukemia (AML). The trial reported a median overall survival of 8.9 months in patients with AML-myelodysplasia-related changes, significantly surpassing the historical benchmark of 2.5 months for similar patients. Additionally, the study achieved a 67% overall response rate, exceeding the targeted 20%. SELLAS has also initiated treatment for the first pediatric patient in a Phase 2 trial of SLS009 for pediatric AML, highlighting its focus on unmet medical needs. The company received the FDA Rare Pediatric Disease Designation for this indication, which could lead to a Priority Review Voucher if approved. Preclinical studies further demonstrated SLS009’s efficacy in reducing leukemia cell populations by up to 97%, particularly in TP53-mutated cells. Analysts from Massachusetts General Hospital have noted the drug’s potential to restore sensitivity to existing therapies. SELLAS continues to evaluate SLS009 in ongoing trials, with an emphasis on safety, efficacy, and biomarker identification.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.